Damian J. Houde

Relay Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index3.2kcitations160works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibroblast Growth Factor Research(94), Eosinophilic Disorders and Syndromes(70), Protein purification and stability(35), Monoclonal and Polyclonal Antibodies Research(20), Mass Spectrometry Techniques and Applications(19)

Publications160 total

Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Appendix S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Nanoscale direct-to-biology optimization of Cdk2 inhibitors
2025· 3 cited
Hydrogen/Deuterium Exchange and Protein Oxidative Footprinting with Mass Spectrometry Collectively Discriminate the Binding of Small-Molecule Therapeutics to Bcl-2
Analytical Chemistry·2025· 3 citedOpen Access
Improved Rapid Equilibrium Dialysis-Mass Spectrometry (RED-MS) Method for Measuring Small Molecule–Protein Complex Binding Affinities in Solution
Journal of the American Society for Mass Spectrometry·2024· 4 cited
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Appendix S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Video S1 Legend from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Video S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Steven A. Berkowitz(20), John R. Engen(8), George M. Bou-Assaf(6), Igor A. Kaltashov(5), Kasper D. Rand(5), Nuruddeen D. Lewis(4), Chang Ling Sia(4), Christine McCoy(4), Jorge Sanchez-Salazar(4), Su Chul Jang(4), Rane A. Harrison(4), Kyriakos D. Economides(4), Yelena Lyubarskaya(4), Rohin Mhatre(4), Alexander M. Taylor(4), Lee Makowski(4), Roxana E. Iacob(3), Kevin Dooley(3), Raymond J. Moniz(3), Bryan D. Choi(3)